Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | HSD17B13 | Q7Z5P4 | 5/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22836722 | 1.00 | IRAK4 (0.41) | IRAK4CRBNHSD17B13TLR8PTGES | |
| SCHEMBL22835873 | 0.90 | HSD17B13 (0.39) | IRAK4CRBNHSD17B13TYK2KDM2B | |
| SCHEMBL22835874 | 0.90 | HSD17B13 (0.39) | IRAK4CRBNHSD17B13TYK2KDM2B | |
| SCHEMBL24508340 | 0.89 | CRBN (0.41) | IRAK4CRBNHSD17B13TLR8PTGES | |
| SCHEMBL29083643 | 0.89 | CRBN (0.41) | IRAK4CRBNHSD17B13TLR8PTGES | |
| SCHEMBL16595488 | 0.89 | BACE1 (0.38) | HSD17B13TLR8TYK2BACE1 | |
| SCHEMBL27213907 | 0.86 | HSD17B13 (0.38) | IRAK4CRBNHSD17B13TLR8TYK2 | |
| SCHEMBL27230890 | 0.86 | HSD17B13 (0.38) | IRAK4CRBNHSD17B13TLR8TYK2 | |
| Hydrochloric Acid SCHEMBL30849268 | 0.85 | HSD17B13 (0.37) | IRAK4CRBNHSD17B13TLR8TYK2 | |
| SCHEMBL22835612 | 0.85 | HSD17B13 (0.41) | IRAK4CRBNHSD17B13TYK2KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885CRBN 187/4885HSD17B13 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.